September 30, 2019 06:46 AM EDTUpdated 05:54 PM
R&D
Pharma
FDA+

FDA clears short­er treat­ment reg­i­men for Ab­b­Vie's hep C treat­ment, Mavyret. Will pa­tients ben­e­fit?

Jason Mast

Editor

Ab­b­Vie $AB­BV has ob­tained FDA ap­proval to ad­min­is­ter its Mavyret he­pati­tis C pill as a two-month reg­i­men, ver­sus the 12-week course it was orig­i­nal­ly cleared …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times